Research Professor
University of Colorado School of Medicine
Michael Szarek, PhD is a research professor in the Division of Cardiology at the University of Colorado School of Medicine, as well as a faculty member of CPC Clinical Research, an Academic Research Organization affiliated with the University of Colorado Anschutz Medical Campus. Michael also has faculty appointments at the Ichan School of Medicine at Mount Sinai and SUNY Downstate Health Sciences University. Michael earned a MS in biostatistics from Harvard School of Public Health and a PhD in biostatistics from New York University. While at Harvard, he was a Schering Plough Scholar and recipient of a National Cancer Institute (NCI) National Research Service Award training grant.
During his career, Michael has supported and served as a member of Executive Steering Committees and Data Safety Monitoring Committees for multiple landmark clinical trials, including MIRACL (atorvastatin), SPRACL (atorvastatin), CARDS (atorvastatin), IDEAL (atorvastatin), TNT (atorvastatin), ILLUMINATE (torcetrapib), ODYSSEY OUTCOMES (alirocumab), BETonMACE (apabetalone), SOLOIST (sotagliflozin), SCORED (sotagliflozin), VOYAGER (rivaroxaban), EVOLVE MI (evolocumab), V2P (inclisiran), BROOKLYN (obicetrapib), BROADWAY (obicetrapib), PREVAIL (obicetrapib), REDUCE-IT (icosapent ethyl), AZURE LDL (AZD0780), AZURE HeFH (AZD0780),and AZURE OUTCOMES (AZD0780). He has also held regulatory affairs leadership positions in industry, including leading the filing of six INDs for cancer therapeutics and interactions with worldwide regulatory agencies in multiple therapeutic areas. Michael has co-authored over 100 peer reviewed scientific publications, is a frequent presenting author at medical conferences, and was previously an editorial board member at the Journal of the American College of Cardiology and JACC Interventions.